Cargando…

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

BACKGROUND: Activated PI3K/AKT/mTOR pathway frequently occurs in metastatic or recurrent cervical carcinomas. However, the clinical benefits of matched therapy, a therapeutic approach targeting a specific mutational abnormality, have not yet been established. METHODS: We analyzed the outcomes of pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Ming-Mo, Liu, Xiaochun, Wheler, Jennifer, Naing, Aung, Hong, David, Coleman, Robert L., Tsimberidou, Apostolia, Janku, Filip, Zinner, Ralph, Lu, Karen, Kurzrock, Razelle, Fu, Siqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294378/ https://www.ncbi.nlm.nih.gov/pubmed/25426553

Ejemplares similares

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
por: Janku, Filip, et al.
Publicado: (2014)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
por: Wheler, Jennifer, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
por: Wheler, Jennifer J., et al.
Publicado: (2016)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Characteristics and survival of patients with advanced cancer and p53 mutations
por: Said, Rabih, et al.
Publicado: (2014)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
por: Janku, Filip, et al.
Publicado: (2011)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
por: Janku, Filip, et al.
Publicado: (2012)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
por: Tang, Chad, et al.
Publicado: (2013)

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
por: Garrido-Laguna, Ignacio, et al.
Publicado: (2012)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
por: Janku, Filip, et al.
Publicado: (2015)

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
por: Janku, Filip, et al.
Publicado: (2015)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
por: Wheler, Jennifer J., et al.
Publicado: (2014)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
por: Tsimberidou, Apostolia M, et al.
Publicado: (2015)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
por: Jiang, Yunyun, et al.
Publicado: (2013)

Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
por: Dembla, Vikas, et al.
Publicado: (2017)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Clinical trial design in the era of precision medicine
por: Fountzilas, Elena, et al.
Publicado: (2022)

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system
por: Janku, Filip, et al.
Publicado: (2015)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

Multiple gene aberrations and breast cancer: lessons from super-responders
por: Wheler, Jennifer J., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j4n06blegsdouafge6or9fjcc9